NCR Online Journal

DelveInsight’s, “Rabies Infection Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Key takeaways from the Rabies Infection Pipeline Report

• DelveInsight’s Rabies Infection Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Rabies Infection treatment.
• The leading Rabies Infection Companies include Synermore Biologics, Sanofi, Anhui Zhifei Longcom Biopharmaceutical, CureVac AG, Yisheng Biopharma, GlaxoSmithKline, Rabies G protein vaccine, Connectyx Technologies, and others
• The promising Rabies infection therapies include Rabies immunoglobulins, SYN023, HRIG, Sterile Water Injection, KamRAB – HRIG, GSK3903133A, VRVg 2, and others
• The companies and academics are working to assess challenges and seek opportunities that could influence Rabies Infection R&D. The therapies under development are focused on novel approaches to treat/improve Rabies Infection.

Get an overview of the Rabies Infection Pipeline landscape @ Rabies Infection Emerging Therapies

Rabies Infection Overview

Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is caused by a lyssavirus (a form of virus that causes encephalitis) that affects the saliva and nervous system. Most cases of rabies in humans are caused by a bite or scratch from an infected animal. It is possible, but rare, for people to get rabies if infectious material from a rabid animal, such as saliva, gets directly into their eyes, nose, mouth, or a wound. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies Infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death. Medical assistance should be obtained as soon as possible after an exposure or possible exposure to rabies. The most effective treatment for rabies is immediate treatment of the wound followed by immunization with the rabies vaccine.

Latest Breakthroughs and Developments in Rabies Infection Treatment Landscape

• In RABV phage display antibody libraries, Kramer et al.48 identified lymphocytes from the blood of participants who had received rabies vaccinations. Utilizing the inactivated virus and pure RABV glycoprotein, the antibodies were chosen. The ideal candidate attached to the AS III was CR4098. A 7 108 clone human phage antibody library was created by Zhao et al.49. They were successful in screening a new rabies mAb called scFv-S12, which had a strong affinity for the rabies virus.
• SYN-023 is a mixture of two anti-rabies humanized monoclonal antibodies, CTB-011 and CTB-012, which bind to 2 different antigenic sites on the rabies glycoprotein. SYN-023 is proposed for use in humans following exposure to the rabies virus. The proposed clinical indication is for post-exposure prophylaxis treatment of rabies in conjunction with rabies vaccine. The proposed mechanism of action is for the mAbs to bind to the rabies virus, which results in virus neutralization in a manner similar to an immune response producing neutralizing antibodies. SYN-023 has been shown to neutralize greater than 15 contemporary wildlife isolates of rabies virus collected in China and 10 isolates collected in the North American. SYN-023 is currently being evaluated in Phase III clinical trial to treat Rabies Infection.
• Freeze-dried human rabies vaccine (Vero cells) is being developed and investigated by Anhui Zhifei Longcom Biopharmaceutical in Phase III stage of development for the treatment of rabies.

Rabies Infection Emerging Drugs

• SYN-023: Synermore Biologics
• Freeze-dried human rabies vaccine: Anhui Zhifei Longcom Biopharmaceutical

Get to know more information about Rabies Infection treatment therapies @ Rabies Infection Clinical Trials

Rabies Infection Pipeline Therapeutics Analysis

There are approx. 10+ key companies which are developing the therapies for Rabies Infection. The companies which have their Rabies Infection drug candidates in the most advanced stage, i.e. Phase III include, Synermore Biologics.

DelveInsight’s Rabies Infection Pipeline Report covers around 10+ products under different phases of clinical development like-

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidate
• Route of Administration

Discover more about therapy set to grab substantial Rabies Infection Pipeline landscape @ Rabies Infection Pipeline Therapeutics Assessment

Scope of the Rabies Infection Pipeline Report

• Coverage- Global
• Rabies Infection Companies include Synermore Biologics, Sanofi, Anhui Zhifei Longcom Biopharmaceutical, CureVac AG, Yisheng Biopharma, GlaxoSmithKline, Rabies G protein vaccine, Connectyx Technologies, and others
• Rabies infection therapies include Rabies immunoglobulins, SYN023, HRIG, Sterile Water Injection, KamRAB – HRIG, GSK3903133A, VRVg 2, and others
• Rabies Infection Pipeline Assessment by Product Type
• Rabies Infection Pipeline Assessment by Stage and Product Type
• Rabies Infection Pipeline Assessment by Route of Administration
• Rabies Infection Pipeline Assessment by Stage and Route of Administration
• Rabies Infection Pipeline Assessment by Molecule Type
• Rabies Infection Pipeline Assessment by Stage and Molecule Type

Table of Content

1. Introduction
2. Executive Summary
3. Rabies Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. SYN-023: Synermore Biologics
8. Mid Stage Products (Phase II)
9. PIKA Rabies vaccine – Yisheng Biopharma
10. Preclinical stage products
11. IMT 504: Connectyx Technologies
12. Inactive Products
13. Rabies Infection Key Companies
14. Rabies Infection Key Products
15. Rabies Infection- Unmet Needs
16. Rabies Infection- Market Drivers and Barriers
17. Rabies Infection- Future Perspectives and Conclusion
18. Rabies Infection Analyst Views
19. Rabies Infection Key Companies
20. Appendix

Got Queries? Reach out for more information on the Rabies Infection Pipeline Report @ Rabies Infection Preclinical and Discovery Stage Products

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/